Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 15/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459850 | 0.87 | EPHX2 (0.52) | CCR3 | |
| SCHEMBL460548 | 0.85 | EPHX2 (0.53) | CCR3HPGDS | |
| SCHEMBL460370 | 0.84 | CCR3 (0.51) | CCR3PRKAA2 | |
| SCHEMBL459356 | 0.83 | CCR3 (0.53) | CCR3CYP2D6 | |
| SCHEMBL459348 | 0.83 | PARP1 (0.43) | CCR3HRH1 | |
| SCHEMBL459399 | 0.82 | CCR3 (0.40) | CCR3HRH1OPRM1HPGDS | |
| SCHEMBL459347 | 0.81 | ALDH1A1 (0.45) | CCR3HPGDS | |
| SCHEMBL460513 | 0.81 | HPGDS (0.44) | HPGDS | |
| SCHEMBL460471 | 0.80 | NPC1 (0.53) | — | |
| SCHEMBL460179 | 0.80 | USP2 (0.46) | CCR3HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181183-B2 | Prostaglandin D synthase inhibitory piperidine compounds | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | claimed |
| EP-2615084-B1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-9181183-B2 | Prostaglandin D synthase inhibitory piperidine compounds | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| EP-2615084-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165438-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | US | disclosed |
| WO-2012033069-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | 大鵬薬品工業株式会社 (JP) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165438-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | PTGIS, PTGS1, PTGDR | CCR3 3502/4885HRH1 2255/4885OPRM1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.